Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 31 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: IBS-D (Diarrhea-predominant) Clear all
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

NCT01553747
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
232
States / cities
Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

NCT01553591
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
257
States / cities
Athens, Alabama • Birmingham, Alabama • Foley, Alabama + 214 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Not applicable Interventional

Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g Bid on Nutritional Status in Subjects With IBS-D

NCT02163213
View directory record Official record
Conditions
Diarrhea-predominant Irritable Bowel Syndrome
Interventions
Serum-derived bovine immunoglobulin protein isolate (SBI)
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Jul 22, 2026, 8:16 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers

Trenev Trio/Healthy Trinity for Symptoms of Diarrhea-predominant Irritable Bowel Syndrome (IBS) and Functional Dyspepsia

NCT01268618
View directory record Official record
Conditions
IBS-D and Functional Dyspepsia
Interventions
Probiotic, Placebo
Dietary Supplement
Lead sponsor
Sprim Advanced Life Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Duluth, Georgia • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2011 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 2 Interventional

Diarrhea Predominant Irritable Bowel Syndrome in Females

NCT00461526
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
crofelemer
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
43
States / cities
Huntsville, Alabama • Chandler, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 22, 2026, 8:16 PM EDT
Completed No phase listed Observational

LOTRONEX® in Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01257477
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Not listed
Lead sponsor
Prometheus Laboratories
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
67
States / cities
Tuscaloosa, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2013 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 2 Interventional

8 Weeks Treatment With DDP225 in Patients With Diarrhea Predominant IBS

NCT00230581
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DDP225
Drug
Lead sponsor
Dynogen Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
5
States / cities
Scottsdale, Arizona • St Louis, Missouri • Great Neck, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2007 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

SBI in Children With d-IBS

NCT02609529
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Medical Food, Placebo
Other
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 3 Interventional

Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)

NCT01100684
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Asimadoline, Placebo
Drug
Lead sponsor
Tioga Pharmaceuticals
Industry
Eligibility
18 Years to 79 Years
Enrollment
611 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
142
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 125 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 2 Interventional Results available

A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome

NCT03931785
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea (IBS-D)
Interventions
MD-7246, Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
80
States / cities
Huntsville, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2021 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Not applicable Interventional

Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS

NCT02358694
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Serum-Derived Bovine Immunoglobulin, Placebo
Dietary Supplement · Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Jul 22, 2026, 8:16 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Rifaximin With NAC in IBS-D

NCT06727422
View directory record Official record
Conditions
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Interventions
rifaximin 66mg + N-acetylcysteine 560mg three times daily, RNIB21 containing rifaximin 132mg + N-acetylcysteine 560mg three times daily, Placebo
Drug
Lead sponsor
Mark Pimentel, MD
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 2 Interventional Results available

Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

NCT02328547
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Fecal microbiota transplantation capsules, Placebo capsules
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
19 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Hamden, Connecticut • New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Jul 22, 2026, 8:16 PM EDT
Terminated Phase 2 Interventional Results available

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

NCT04043455
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Olorinab, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
69
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Analyzing IBS to Identify Biomarkers and Microbiome Signatures

NCT02419963
View directory record Official record
Conditions
Diarrhoea Predominant Irritable Bowel Syndrome, IBS
Interventions
endoscopy for tissue biopsy, Blood Sample, Stool Sample
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 2 Interventional

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

NCT01494233
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
250 mg LX1033 tablets, Placebo tablet
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
81
States / cities
Huntsville, Alabama • Tempe, Arizona • Tucson, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Jul 22, 2026, 8:16 PM EDT
Terminated Phase 2 Interventional

Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01887002
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
ONO-2952, Placebo comparator
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2016 · Synced Jul 22, 2026, 8:16 PM EDT
Terminated Phase 2 Interventional

Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D).

NCT06153420
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
CIN-103, Placebo
Drug
Lead sponsor
CinPhloro Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Dothan, Alabama • Huntsville, Alabama • Phoenix, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2025 · Synced Jul 22, 2026, 8:16 PM EDT
Terminated Phase 1 Interventional

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

NCT04655599
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Olorinab, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 2 Interventional Results available

Does Welchol (Colesevelam Hydrochloride) Improve Colonic Transit in Diarrhea-predominant Irritable Bowel Syndrome (D-IBS)?

NCT00911612
View directory record Official record
Conditions
Irritable Bowel Syndrome, Diarrhea
Interventions
Colesevelam, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 3, 2012 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 2 Interventional

Efficacy, Safety and Tolerability of DNK333 (25 and 100 mg Bid) in Women With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT00699166
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
DNK333
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
29
States / cities
Anniston, Alabama • Huntsville, Alabama • Northport, Alabama + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2008 · Synced Jul 22, 2026, 8:16 PM EDT
Completed No phase listed Observational

Retrospective Study of IBS-D Patients Previously Receiving SBI

NCT02661425
View directory record Official record
Conditions
Diarrhoea Predominant Irritable Bowel Syndrome
Interventions
EnteraGam
Other
Lead sponsor
Entera Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Greenwich, Connecticut • Hamdon, Connecticut • Coral Springs, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2016 · Synced Jul 22, 2026, 8:16 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D

NCT02239926
View directory record Official record
Conditions
Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 2 Interventional

A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome

NCT00101725
View directory record Official record
Conditions
Irritable Bowel Syndrome, Colonic Diseases, Diarrhea, Gastrointestinal Disease
Interventions
crofelemer
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
29
States / cities
Huntsville, Alabama • Chandler, Arizona • North Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 22, 2026, 8:16 PM EDT